Diagnostic Role and Prognostic Significance of miRNA-133a in Acute Myocardial Infarction

Abstract

Background: Despite improvement in acute ST elevation myocardial infarction (STEMI)) therapy, 30% of patients have LV remodeling after myocardial infarction (MI) . It was discovered that miRNA-133a, plays a role in the initial pathophysiology of MI . Objectives: to evaluate diagnostic and prognostic role of miRNA-133a in STEMI. Methods: a prospective study that was conducted during 1.5 years. It had two groups: Group I which consisted of 100 patients with acute STEMI, all managed by 1ry PCI , and Group II (n=50) as controls .They underwent comprehensive clinical evaluation, laboratory testing for miRNA-133a , serum high sensitivity cardiac troponin and 2D echocardiographic examination. after 6 months follow up , Group I was divided into subgroup I with LV remodeling based on  20 increase in LVED volume after 6 months and IB without LV remodeling and again was subdivided according to the occurrence of the major adverse cardiovascular events (MACE) during 6-months follow-up. Results: Group I showed significantly higher levels of miRNA-133a expression (44.22 ± 10.98 vs. 4.31 ± 1.58, p 0.001) than group II. The level of miRNA-133a was not significantly different in patients with LV remodeling and patients with early and late complications. According to a multivariate analysis, LVED was the best predictor of LV remodeling. Conclusions: miRNA-133 a was found to be a better diagnostic biomarker for Acute STEMI .It could neither predict myocardial remodeling, nor early or late complications as well as fate of the patients after acute STEMI.